Document:

Exhibit

 

EXTENSION AND CONFIRMATION AGREEMENT

 

Made this 15th day of December 2011 (the
"Effective Date") by and between Viral Genetics, Inc., a Delaware corporation (the "Company"), and Marshall
C. Phelps, Jr. ("Consultant").

 

WHEREAS Company and Consultant are party to a Consulting
Agreement dated January 1, 2008 (the "Agreement") that they verbally agreed to extend for one year on or about each of
December 31, 2009 and December 31, 2010 as provided for in Section 1 therein, and are mutually desirous of memorializing
those extensions, and further desire to extend the Agreement for an additional year through December 31, 2012.

 

NOW, THEREFORE, for good and lawful consideration
and of the mutual covenants contained herein and the mutual benefits to be derived hereunder, the parties agree as follows:

 

		1.	Consultant is owed and Company shall deliver a total of
400,000 shares of common stock of Company for services provided for the two years ending December 31, 2011.

		2.	The Term of the Consulting Agreement is hereby extended
until December 31, 2012.

		3.	All other terms and conditions of the Consulting Agreement,
including, without limitation, those in Exhibit A therein entitled "Viral Genetics Intellectual Property Agreement",
shall continue in full force and effect.

 

AGREED and entered into as of the date affixed hereof.

 

COMPANY:

VIRAL GENETICS, INC.

 

By /s/ Haig Keledjian                           

Duly Authorized Officer

 

CONSULTANT:

 

/s/ Marshall C. Phelps, Jr.                               

Marshall C. Phelps, Jr.Exhibit 10.66

 

CANCELLATION AGREEMENT

 

CANCELLATION AGREEMENT dated as of January 1, 2011, by and between
VIRAL GENETICS, INC. (the "Company"), and IMPERIAL CONSULTING NETWORK, INC. ("ICN"). Each of the Company and
ICN is also sometimes herein referred to as a "Party" and collectively as the "Parties".

 

WHEREAS, the Company and ICN are parties to a Marketing Advertising
and Financial Agreement dated as of December 1, 2010 (the "Agreement"); and

 

WHEREAS, the Company and ICN desire to terminate
the Agreement as provided for herein.

 

NOW, THEREFORE, in consideration of these premises, and for
good and valuable consideration, the receipt and legal adequacy of which is hereby acknowledged, it is agreed as follows:

 

1.Viral has decided that it does not desire to have itself
profiled on ICN's television program, "Wide World of Stocks ®" and has informed ICN of that decision. Viral acknowledges
and agrees that ICN has performed substantially all of the services relating to the production of the program (including taping
the program) and has incurred all of the cost and expenses associated with the production and distribution of the program.

 

2.ICN hereby agrees to the termination of the Agreement
and that it will not distribute the program.

 

3.Notwithstanding the termination of the Agreement, at the
Company's request, for no compensation or consideration to ICN, ICN has agreed to provide information about the Company to the
general public and financial public, including by engaging third parties chosen by ICN when requested by the Company, through the
period ending December 31, 2011.

 

4.In consideration of agreeing to the cancellation of the
Agreement, the Company agrees to issue to ICN, 4,000,000 shares of the Company's common stock as of the date of this Agreement.

 

5.ICN agrees that except for the payment set forth in Section
4 hereof, and the 4,000,000 shares of the Company's common stock previously issued to ICN pursuant to the Agreement, ICN shall
not be entitled to any other compensation under the Agreement, including, without limitation, the Warrants (as such term is defined
in the Agreement) provided for in the Agreement.

 

6.Amendment; Waiver. Any amendment, modification
or waiver of any term or provision of this Agreement shall only be effective if such amendment, modification or waiver is evidenced
by an instrument in writing duly executed by each of the Parties hereto. No waiver by a Party of any term or provision of this
Agreement shall be deemed to be a waiver of any preceding or subsequent breach of the same or similar nature or of any other term
or provision of this Agreement. Any waiver shall be limited to the specific instance for which it is given. Any course of dealing
between the Parties shall not be considered an amendment or modification of this Agreement or a waiver of any term or provision
thereof.

    	1

    	 

    

 

 

7.Governing Law. This Agreement shall be governed
by and construed and enforced in accordance with the laws of the State of New York, without regard or reference to any of its
choice of laws or conflicts of laws principles which would result in the application of the laws of another jurisdiction.

 

8.Assignment, etc. This Agreement may not be assigned
by either Party . Notwithstanding the immediately preceding sentence, either Party may assign this Agreement to any entity that
purchases all or substantially all of the assets of such party; provided that written notice of such assignment is given to the
other Party within fifteen (15) business days prior to the effectiveness of such assignment, and the assignee assumes in writing
all of the obligations of the assigning Party hereunder to the reasonable satisfaction of the non-assigning Party. This Agreement
shall inure to the benefit of, and shall be binding upon, the Parties, their respective successors (whether by merger or consolidation,
recapitalization or other similar transaction) and their permitted assignees. This Agreement is not intended to create any right
in favor of, or benefit for, any third party who is not a signatory hereto.

 

9.Drafting History. In resolving any dispute or
controversy arising out of or relating to this Agreement or in connection with construing any term or provision in this Agreement,
there shall be no presumption made or inference drawn because of the inclusion of a provision not contained in a prior draft or
the deletion of a provision contained in a prior draft. The Parties acknowledge and agree that this Agreement was negotiated and
drafted with each Party being represented by competent legal counsel of its choice and with each Party having an opportunity to
participate in the drafting of the provisions hereof and shall therefore this Agreement shall be construed and interpreted as
if drafted jointly by the Parties and not with any presumption against either of the Parties.

 

10.Complete Agreement. This Agreement constitutes
the entire understanding and agreement of the Parties with respect to the subject matter hereof, and it supersedes all prior and/or
contemporaneous understandings and agreements between USRN, on the one hand, and the Producer, on the other hand, whether oral
or written, with respect to such subject matter, all of which are merged herein. There are no representations, warranties, agreements
or promises between the Parties with respect to such subject matter, except those which are expressly set forth herein.

 

11.Headings, Counterparts. The section headings
contained in this Agreement are inserted herein for the purpose of convenience and reference only and they are not to be given
any substantive effect, nor shall they be used or have any effect upon the construction or interpretation of any term or provision
hereof. Any reference to the masculine, feminine or neuter gender shall be a reference to such other gender as if appropriate.
References to the singular shall include the plural and vice versa. This Agreement shall be effective when duly executed counterparts
are executed and delivered by each of the Parties. This Agreement may be executed in multiple counterparts (and may be executed
by facsimile, PDF or electronic signature, which shall constitute a legal and valid signature for purposes hereof), each of which
shall constitute an original, and all of which, when take together, shall constitute one and the same document. The Parties acknowledge
and agree that this Agreement is effective as of its specified date regardless of the fact that it is being executed by either
of the Parties on another date (including a later date). Facsimile or PDF counterparts of this Agreement shall be deemed to be
considered original and valid counterparts hereof.

 

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

    	2

    	 

    

 

 

IN WITNESS WHEREOF, each of the Company
and ICN has caused this Agreement to be executed by one of its duly authorized officers as of the date first written above.

 

	 	VIRAL GENETICS, INC.
	 	 
	 	By:  /s/ Haig Keledjian
	 	Name:  Haig Keledjian
	 	Title:  President
	 	 
	 	 
	 	IMPERIAL CONSULTING NETWORKING, INC.
	 	 
	 	By:  /s/ Hugh Ausia
	 	Name:  Hugh Ausia
	 	Title:  President

 

 

 

    	3THE SECURITIES REPRESENTED BY THIS INSTRUMENT
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN
CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT UNLESS AN EXEMPTION FROM REGISTRATION IS AVAILABLE UNDER THE SECURITIES ACT OF 1933 (THE "SECURITIES ACT").

 

RESTATED CONVERTIBLE DEBENTURE

 

	$73,000.00  	As of January 27, 2012

 

For value received,
Viral Genetics, Inc., a Delaware corporation (the "Company"), promises to pay to the order of DMBM Inc. (the "Holder"),
the principal sum of SEVENTY THREE THOUSAND DOLLARS AND NO CENTS or the aggregate outstanding principal amount hereof, whichever
is less (the "Principal"), represents various loans (each a "Loan") made by the Holder to the Company between
January 1, 2012 and January 27, 2012, on the dates and in the amounts specified on Schedule A attached hereto and to pay interest
on the outstanding principal amount of this Convertible Debenture (this "Debenture") as provided herein.

 

1. Definitions. The following
terms shall have the definitions set forth in this Section 1:

 

(a) "Business Day"
means any day on which banks are open for business in both the State of California and the State of New York.

 

(b) "Common Stock"
means the Company's common stock, par value $0.0001 per Share.

 

(c) "Conversion Price"
shall be $0.0005 per Share.

 

(d) "Shares" means
shares of Common Stock.

 

(e) "Trading Day"
means a calendar day on which the Shares are quoted for trading on the Trading Market.

 

(f)"Trading
Market" means the following markets or exchanges on which the Shares are listed or quoted for trading on the date in question:
The Over The Counter Bulletin Board, the PinkSheets, the Nasdaq SmallCap Market, the American Stock Exchange, the New York Stock
Exchange, the Nasdaq National Market, the Toronto Stock Exchange, the TSX Venture Exchange, or any other securities exchange registered
with the United States Securities and Exchange Commission.

 

2. Loans. Each
Loan made by the Holder to the Company evidenced by this Debenture, shall be set forth on Schedule A attached hereto. The Holder
is authorized by the Company to modify Schedule A from time to time to reflect the amount of any partial conversion of this Debenture.

 

 

    	1

    	 

    

3. Interest. Interest
on the outstanding Principal amount of this Debenture will accrue at a rate equal to one percent (1%) per annum from the date of
the making of each Loan as set forth on Schedule A. Interest will be computed on the basis of a year of 12 months, each having
30 days, and will be paid on the Maturity Date and upon any permitted prepayment of this Debenture.

 

4. Repayment. The
Company shall pay the Principal amount of this Debenture, together with all accrued and unpaid interest, to the Holder on May 31,
2013 (the "Maturity Date").

 

5. Payment. All
payments due under this Debenture shall be made in either the lawful money of the United States of America or in Shares, as determined
by the Company in its discretion in accordance with Section 5 hereof, without set-off, deduction, demand or notice.

 

(a)Form
of Payment. Five (5) business days prior to the Maturity Date, the Company, at its sole discretion, shall notify the Holder
whether the payment due on the Maturity Date shall be made in cash or in Shares.

 

(b)Payment
in Cash. All payments in cash shall be made to the Holder by check or by wire transfer to such bank as the Holder may advise
the Company in writing.

 

(c)Payment
in Shares. The number of Shares issuable upon a payment being made in Shares shall be calculated by dividing the aggregate
amount due on the Maturity Date by the Conversion Price. No fractional Shares will be issued upon conversion of this Debenture
or a payment by the Company in Shares. In lieu of any fractional Share to which the Holder would otherwise be entitled upon a payment
in Shares, the Company will pay to the Holder in cash the amount of the unpaid or unconverted Principal and interest balance of
this Debenture that would otherwise be paid or converted into such fractional Share. Shares issued hereunder shall be transmitted
by the transfer agent of the Company to the Holder either by crediting the account of the Holder's designated broker with the Depository
Trust Company through its Deposit Withdrawal Agent Commission ("DWAC"), or, if so elected by Holder, by physical delivery
of certificates to Holder's address within five (5) Trading Days from the Due Date. If the Company fails for any reason to deliver
to the Holder the Shares by the requisite delivery date, the Company shall pay to the Holder, in cash, as liquidated damages and
not as a penalty, for each $1,000 of Shares not timely delivered, $5 per Trading Day (increasing to $10 per Trading Day on the
fifteenth (15) Trading Day after such liquidated damages begin to accrue) for each Trading Day after such requisite delivery date
until such Shares are delivered. In addition to any other rights available to the Holder, if the Company fails to cause its transfer
agent to deliver to the Holder the Shares on or before the requisite delivery date, and if after such date the Holder is required
by its broker to purchase (in an open market transaction or otherwise), or the Holder's brokerage firm otherwise purchases, Shares
to deliver in satisfaction of a sale by the Holder of the Shares which the Holder anticipated receiving pursuant to this Debenture
(a "Buy-In"), then the Company shall (1) pay in cash to the Holder the amount by which (x) the Holder's total purchase
price (including brokerage commissions, if any) for the Shares so purchased exceeds (y) the amount obtained by multiplying
(A) the number of Shares that the Company was required to deliver to the Holder multiplied by (B) the price at which the sell order
giving rise to such purchase obligation was executed, and (2) deliver to the Holder the number of Shares that would have been issued
had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Shares
having a total purchase price of $11,000 to cover a Buy-In with an aggregate sale price giving rise to such purchase obligation
of $10,000, under clause (1) of the immediately preceding sentence the Company shall be required to pay the Holder $ 1,000. The
Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the Buy-In and, upon
request of the Company, commercially reasonable evidence of the amount of such loss.

 

 

    	2

    	 

    

 

(d)Adjustments.
If the Company, at any time while this Debenture is outstanding subdivides outstanding Shares into a larger number of shares
or combines (including by way of reverse stock split) outstanding Shares into a smaller number of shares, then the Conversion Price
shall be multiplied by a fraction of which the numerator shall be the number of Shares outstanding immediately before such event
and of which the denominator shall be the number of Shares outstanding immediately after such event.

 

6. Prepayment. This
Debenture may not be prepaid by the Company without the prior written consent of the Holder, except as provided in Section 7 of
this Debenture.

 

7. Conversion. At
any time prior to five (5) business days prior to the Maturity Date, all or any portion of the Principal amount of this Debenture,
together will accrued interest thereon, may be converted at the option of the Holder, at any time and from time to time, in the
minimum principal amount of $5,000 and integral multiples of $1,000 thereafter, upon not less than two (2) three (3) Business Days
after the Company's receipt of the Conversion Notice (as hereinafter defined) from the Holder and payment in full of the Conversion
Price as then in effect. Each "Conversion Notice" shall mean a written notice from the Holder informing the Company of
the date of the conversion, the principal amount of this Debenture being converted, the number of shares of Common Stock to be
received upon conversion and confirming that the Conversion Price will be paid in cash. The Conversion Price shall be paid by certified
check or by wire transfer of immediately available funds to a bank account designated by the Company in writing. Within three (3)
Business Days after payment of the Conversion Price, the Company will deliver a certificate for the shares of Common Stock issued
upon conversion to the Holder, or at the Holder's request, to a brokerage account for the benefit of Holder. The Company shall
at all times reserve for issuance a number of shares of Common Stock sufficient to satisfy the conversion feature of this Debenture.
The number of shares of Common Stock issuable upon the conversion of all or a portion of this Debenture shall be equal to the Principal
amount of this Debenture being converted divided by the Conversion Price. For purposes hereof, any partial conversion of this Debenture,
each Loan shall be considered separate and distinct indebtedness of the Company to the Holder for purposes of determining the holding
period of each item of indebtedness represented by the Loan. Notwithstanding anything set forth herein, in no event shall the Holder
be entitled to convert this Debenture for a number of shares of Common Stock in excess of that number of shares of Common Stock
which, upon giving effect to such conversion, would cause the aggregate number of shares of Common
Stock beneficially owned by the Holder and its affiliates to exceed 9.99% of the outstanding shares of the Common Stock
following such conversion. Notwithstanding receipt of a Conversion Notice, the Company shall have the right to prepay this Debenture
in the amount being converted if the principal amount to be converted together with accrued interest thereon is paid in immediately
available funds within one (1) business day after the date of the

 

 

 

    	3

    	 

    

 

 

8. Seniority. The
indebtedness represented by this Debenture is and shall be an obligation of the Company ranking senior in right of payment, liquidation
and otherwise to any future indebtedness and other obligations of the Company. The Company will not create any indebtedness that
is senior in priority to the indebtedness represented by this Debenture.

 

9. Default. Any
one of the following occurrences shall constitute an "Event of Default" under this Debenture:

 

(a)failure of
Company to pay any amount that it payable under this Debenture on the Due Date, provided that such failure is not cured within
a grace period of ten (10) calendar days; or

 

(b)failure to
comply with or perform any other agreement or covenant of the Company contained herein, which failure does not otherwise constitute
an Event of Default, provided that such failure has not been cured within thirty (30) calendar days written notice by Holder to
the Company; or

 

(c) there shall
occur any default or event of default, any similar event, any event that requires the prepayment of borrowed money or permits the
acceleration of the maturity thereof, or any event or condition that might become any of the foregoing with notice or the passage
of time or both, under the terms of any evidence of indebtedness or other agreement issued or assumed or entered into by the Company,
or under the terms of any document or instrument under which any such evidence of indebtedness or other agreement is issued, assumed,
secured, or guaranteed, and such event shall continue beyond any applicable notice, grace or cure period, provided that such condition
shall not have been cured within thirty (30) calendar days of notice by Holder; or

 

(d)the Company
shall fail to maintain its existence in good standing in its state of incorporation; provided that such condition shall
not have been cured within thirty (30) calendar days of notice by Holder; or

 

(e)a judgment
or settlement shall be entered or agreed to in any proceeding which would reasonably be expected to have a material and adverse
effect on the ability of the Company to repay this Debenture; or any garnishment, summons, writ of attachment, citation, levy or
the like is issued against or served upon Holder for the attachment of any property of the Company in Holder's possession or control,
provided that such condition shall not have been cured within thirty (30) calendar days of notice by Holder of such condition;
or

 

 

 

    	4

    	 

    

(f)
any Share issued pursuant to this Debenture shall not be duly authorized, validly issued, fully paid or nonassessable, provided
that such condition shall not have been cured within ninety (90) calendar days of notice by Holder of such condition; or

 

(g) the Company shake
make a voluntary filing for bankruptcy under Title 11, Chapter 7 of the United States Code; or

 

(h) there shall
be appointed a receiver or trustee to take possession of the property or assets of the Company under Title 11, Chapter 7 of the
United States Code.

 

 

10. Remedies. Upon
the occurrence and during the continuance of an Event of Default, this Debenture and shall become immediately due in full, and
unpaid amounts hereunder will accrue interest at the rate equal to the stated rate plus 5.00% per annum, and Holder may exercise
any rights and remedies under this Debenture, any Transaction Document or other document or instrument and at law or in equity.
The time of payment of this Debenture is also subject to acceleration if an Event of Default occurs. Notwithstanding the foregoing,
the entire unpaid Principal sum of this Debenture, together with accrued and unpaid interest thereon, shall become immediately
due and payable upon any of the Events of Default set forth in this Debenture.

 

11. Transfer; Successors
and Assigns. The terms and conditions of this Debenture shall inure to the benefit of and be binding upon the respective successors
and assigns of the parties. At the election of the Holder, but subject-to compliance with applicable securities laws, this Debenture
may be assigned or transferred by the Holder, in whole or in part, upon surrender of this Debenture, duly endorsed, and accompanied
by a duly executed written instrument of transfer in customary form, following which a new Debenture for the same principal amount
and interest will be issued to, and registered in the name of, the transferee. If less than the entire amount of this Debenture
is transferred or assigned, the Company will issue new Debentures to the transferee, in the amount transferred or assigned, and
to the Holder, in the remaining Principal amount hereof after the transfer or assignment. This Debenture shall be binding upon
and inure to the benefit of the Company and the Holder, their successors and permitted assigns and the transferees of the Holder.

 

12. Governing Law.
This Debenture and all acts and transactions pursuant hereto and the rights and obligations of the Company and the Holder shall
be governed, construed and interpreted in accordance with the laws of the State of New York, without giving effect to any of its
principles of conflicts of law or choice of law principles which would result in the application of the laws of another jurisdiction.

 

13. Notices. Any
notice required or permitted by this Debenture shall be in writing and shall be deemed sufficient upon receipt, when delivered
personally or by courier, overnight delivery service or confirmed facsimile, or 96 hours after being deposited in the U.S. mail
as certified or registered mail with postage prepaid, if such notice is addressed to the party to be notified at such party's address
or facsimile number as set forth herein or as subsequently modified by written notice.

 

 

 

    	5

    	 

    

 

14. Amendments
and Waivers. This Debenture may only be amended, modified or waived by a written instrument executed by the Company and the
Holder. Any amendment or waiver effected in accordance with this Section 14 shall be binding upon the Company, the Holder and
each transferee or permitted assigns of any Debenture.

 

15. Loss of Debenture.
Upon receipt by the Company of a customary representation by the Holder of the loss, theft, destruction or mutilation of this
Debenture or any Debenture exchanged for it, and a customary indemnity undertaking by the Holder (in case of loss, theft or destruction)
or surrender and cancellation of such Debenture (in the case of mutilation), the Company will make and deliver in lieu of such
Debenture a new Debenture of like tenor.

 

16. Waiver of Presentment,
etc. The Company hereby expressly waives presentment, demand for payment, dishonor, notice of dishonor, protest, notice of
protest and any other formality upon the occurrence of an Event of Default.

 

17. Entire Understanding.
This Debenture sets forth the entire understanding agreement of the Company and the Holder with respect to the subject matter
hereof and it supersedes all prior and/or contemporaneous understandings and agreements with respect to such subject matter, all
of which are merged herein, and it specifically amends and restates a Debenture dated this date in the same principal amount hereof,
which did not accurately reflect the understanding and agreement of the Company and the Holder.

 

18. Costs and Fees.
The Company agrees to pay all costs, expenses, including, without limitation, reasonable attorneys' fees and disbursements,
incurred by the Holder in endeavoring to collect any amounts payable hereunder (including, without limitation, amounts payable
in Shares) which are not paid when due or otherwise in enforcing any provision of this Debenture and any of the rights and remedies
of the Holder under this Debenture, at law or in equity.

 

[signature page follows]

 

 

 

 

    	6

    	 

    

 

IN
WITNESS WHEREOF, this Debenture has been executed by a duly authorized officer of the Company as of the date first written above.

 

 

COMPANY

 

VIRAL GENETICS, INC.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    	7

    	 

    

 

Schedule A

 

	Date of Loan	 	 	 	Amount of Loan	 
	 	 	 	 	 	 	 
	01/03/2012	 	Viral : (Bank of America)	 	$	2,000	 
	01/05/2012	 	Viral : (Bank of America)	 	$	6,000	 
	01/09/2012	 	Viral : (Bank of America)	 	$	1,000	 
	1/13/12	 	Viral Genetics Inc	 	$	5000	 
	1/13/12	 	Viral Genetics Inc	 	$	12,000	 
	1/13/12	 	Viral Genetics Inc	 	$	5000	 
	1/17/12	 	Viral Genetics Inc	 	$	3000	 
	1/19/12	 	Viral Genetics Inc	 	$	8000	 
	1/20/12	 	Viral Genetics Inc	 	$	2000	 
	1/24/12	 	Viral Genetics Inc	 	$	4000	 
	1/24/12	 	Viral Genetics Inc	 	$	5000	 
	1/26/12	 	Viral Genetics Inc	 	$	10,000	 
	1/27/12	 	Viral Genetics Inc	 	$	5000	 
	1/27/12	 	Viral Genetics Inc	 	$	5000	 
	 	 	 	 	 	 	 
	JANUARY TOTAL =	 	 	 	$	 73,000	 

 

 

 

    	8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]